Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 110 results for anticoagulation

  1. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  2. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  3. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  4. Further research should report:

    dependent on dialysis) details of the procedure technique duration of anticoagulation patient outcomes (including planned and unplanned...

  5. Interventional procedures advisory committee members

    Interventional Procedures Advisory Committee members

  6. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (IPG773)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

  7. Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease (IPG769)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

  8. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.

  9. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  10. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  11. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  12. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  13. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.

  14. Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome (IPG724)

    Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. This involves opening the chest through the breastbone and wrapping a mesh around the outside of the aorta at the part closest to the heart.

  15. Aspirin and anticoagulant treatment for acute ischaemic stroke: Does modified-release dipyridamole or clopidogrel with aspirin improve outcome compared with aspirin alone when administered early after acute ischaemic stroke?

    ischaemic stroke improves outcome compared with no treatment or early anticoagulation. In the secondary prevention of stroke, the...

  16. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  17. Atrial Fibrillation (AF) Holistic Care Pathway

    practice were chosen and incorporated locally. Examples include: Anticoagulation assessment with better uptake of DOAC. Address...

  18. Anticoagulation and antiplatelet therapy: In adults with biological valve replacement, what effect does anticoagulation or antiplatelet therapy have on long-term valve function and outcomes?

    Question Anticoagulation and antiplatelet therapy: In adults with biological valve replacement, what effect does...

  19. Anticoagulation and antiplatelet therapy: What is the clinical and cost effectiveness of single or dual antiplatelet therapies or anticoagulants compared with placebo after transcatheter or surgical valve replacement (implantation) with biological prosthesis and after valve repair?

    Recommendation ID NG208/22 Question Anticoagulation and antiplatelet therapy: What is the clinical and cost effectiveness of single or

  20. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  21. Venous thromboembolism in adults (QS201)

    This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.

  22. Stopping anticoagulation after ablation: What is the clinical and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation?

    Question Stopping anticoagulation after ablation: What is the clinical and cost effectiveness of stopping anticoagulation...

  23. Stopping anticoagulation after resolution of postoperative atrial fibrillation: What is the clinical and cost effectiveness of stopping anticoagulation in people whose postoperative atrial fibrillation after cardiac surgery has resolved?

    Stopping anticoagulation after resolution of postoperative atrial fibrillation: What is the clinical and cost effectiveness of stopping...

  24. NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination

    NICE has today (29 July 2021) published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.

  25. Reducing the risk of stroke in AF: using the NICE PDA with patients not currently treated with anticoagulants

    Some practices initiated anticoagulation themselves, but others referred their patients to the secondary care...

  26. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  27. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  28. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  29. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  30. Improving the care of patients discharged following a pulmonary embolism, in line with NICE Guidelines (NG158)

    about 2–8% in the 3 months following diagnosis. The benefit of early anticoagulation to improve mortality and decrease recurrent...

  31. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

  32. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  33. The effect of COVID-19 related lockdown on patients taking warfarin

    are tested at their GP surgery they may not have any contact with the anticoagulation team regarding such issues We noted that pre COVID...

  34. Safe and effective management of stroke prevention in atrial fibrillation

    comprises of anticoagulants, with clear evidence to support the fact that anticoagulation with vitamin K antagonists (VKAs) or direct...

  35. Stroke Prevention in Atrial Fibrillation (AF) Protect and Perfect – Optimising anticoagulation treatment

    clinicians to Protect and Protect patients diagnosed with AF on appropriate anticoagulation therapy in line with NICE guidance, thereby...

  36. Improving patients time in range on warfarin

    aimed to safely manage patients according to NICE guidelines regarding anticoagulation. Patients on warfarin need tight control over...

  37. Improving anticoagulation in patients with atrial fibrillation using the GRASP AF audit tool (part of the GRASP suite of tools delivered by PRIMIS in partnership with NHS England)

    being at high risk of stroke, based on the relevant recommendations for anticoagulation in NICE guidance for AF (NG196). This example...

  38. Accelerated Implantable Cardiac Monitor (ICM) insertion for the detection of Atrial Fibrillation in Cryptogenic Stroke

    performed remotely by the cardiac physiology team. If AF was detected, anticoagulation therapy was initiated without delay by the nurse...

  39. In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anticoagulation drug therapy

    or more, the percentage of patients who are currently treated with anticoagulation drug therapy Subject(s): Atrial fibrillation

  40. NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation

    NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).

  41. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  42. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  43. DOAC Dipstick for detecting direct oral anticoagulants (MIB248)

    NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .

  44. AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)

    NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .

  45. Using implantable cardiac monitors to detect atrial arrhythmias (fibrillation/flutter) after cryptogenic stroke

    identifying the cause and initiating appropriate secondary prevention (anticoagulation in case of atrial fibrillation or AF) To increase...

  46. Implementing point-of-care D-dimer tests for deep vein thrombosis (DVT)

    states that if a D-dimer test cannot be obtained within 4 hours, interim anticoagulation should be given. If a person has a low...

  47. Zio XT for detecting cardiac arrhythmias (MTG52)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

  48. Introducing implantable cardiac monitors to support detection of atrial fibrillation after cryptogenic stroke at Salford Royal NHS Trust

    of Unknown Source (ESUS) Patients considered suitable for long term anticoagulation Modified Rankin Score (mRs) ≤3 See key learning...

  49. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.